Effects comparison of repaglinide and metformin for treating secondary failure diabetes mellitus: a meta-analysis
10.3969/j.issn.1671-8348.2018.12.020
- VernacularTitle:瑞格列奈与二甲双胍治疗继发性失效糖尿病疗效的Meta分析
- Author:
Qian ZOU
1
;
Xiguang MAO
;
Suhua TU
;
Guangyu ZHANG
;
Shufang ZOU
;
Qin WAN
Author Information
1. 西南医科大学附属医院妇产科
- Keywords:
repaglinide;
metformin;
secondary failure diabetes;
curative effect comparison;
meta-analysis
- From:
Chongqing Medicine
2018;47(12):1644-1649
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically evaluate the clinical effect and safety of repaglinide and metformin for treating diabetes mellitus (MD) of secondary failure of sulfonylurea (SFS).Methods The randomized controlled trials (RCT) at home and abroad on the comparison of effect and safety of repaglinide and metformin in treating MD with SFS were retrieved.The modified Jadad scale was employed to evaluate the literature quality.The RevMan5.3.1 software was used for conducting the meta analysis.Results A total of 10 RCT were included.The meta-analysis results showed that compared with metformin for treating MA with SFS,repaglinide decreased the fasting blood glucose effectively (MD=-2.30,95 ％ CI:-2.53--2.06,P＜0.01),increased the fasting C-peptide (MD=0.06,95％CI:0.02-0.11,P=0.01),reduced the postprandial 2 h blood glucose (MD=-2.17,95 ％CI:-2.44-1.89,P＜0.01) and decreased glycosylated hemoglobin (MD=-2.60,95％CI:-3.21--2.00,P＜0.01) as well as the adverse reactions (RR=0.05,95％CI:0.02-0.09,P＜0.01).However,there was no statistical difference in fasting insulin between the repaglinide and metformin groups (MD=0.18,95％CI:-0.18-0.54,P=0.32).Conclusion Currently evidences suggest that repaglinide is superior to metformin for treating MD with SFS.
